- Comorbid anxiety at baseline is associated with triple the risk for a poor IBD-related outcome in patients with inflammatory bowel disease (IBD), but there is no increased risk with comorbid depression.
Why this matters
- Evaluation and treatment of anxiety at the beginning of care may improve IBD-related outcomes.
- Prospective cohort of 414 patients with IBD aged ≥16 years at 2 sites in Ontario, Canada (2008-2016).
- Patients were evaluated at baseline for IBD by Rome III questionnaire, and for anxiety and depression by the Hospital Anxiety and Depression Scale (HADS).
- Poor IBD-related outcomes included IBD-related hospitalization, emergency department visit, and recurrent course of corticosteroids during follow-up.
- Funding: None disclosed.
- Mean duration of follow-up was 3.8-4.1 years.
- Comorbid anxiety at baseline (HADS subscore >11), but not depression, was associated with increased risk for poor outcomes (aOR, 3.36; P=.003) vs no elevated anxiety (HADS subscore ≤11), after adjustment for covariates.
- Other factors increased risk for poor outcomes:
- severity of disease at baseline (aOR, 1.46; P=.04),
- prior IBD-related surgery (aOR, 5.25; P<.001>
- elevated C-related peptide (≥5 mg/L) at baseline (aOR, 3.23; P=.002), and
- longer duration of follow-up (aOR, 1.50; P<.001>
- Endoscopy not uniformly used for disease severity.